(E)-3-[2-bromo-5-methyl-3-[[(2S)-oxetan-2-yl]methyl]imidazol-4-yl]-2-fluoroprop-2-enoic acid
C11H12BrFN2O3 — CID 172694193
Data last refreshed: (MolForge compound catalog, from PubChem)
About (E)-3-[2-bromo-5-methyl-3-[[(2S)-oxetan-2-yl]methyl]imidazol-4-yl]-2-fluoroprop-2-enoic acid
(E)-3-[2-bromo-5-methyl-3-[[(2S)-oxetan-2-yl]methyl]imidazol-4-yl]-2-fluoroprop-2-enoic acid (PubChem CID 172694193) has the molecular formula C11H12BrFN2O3 and a molecular weight of 319.13 g/mol. Its IUPAC name is (E)-3-[2-bromo-5-methyl-3-[[(2S)-oxetan-2-yl]methyl]imidazol-4-yl]-2-fluoroprop-2-enoic acid.
Molecular Properties
| Compound Name | (E)-3-[2-bromo-5-methyl-3-[[(2S)-oxetan-2-yl]methyl]imidazol-4-yl]-2-fluoroprop-2-enoic acid |
|---|---|
| PubChem CID | 172694193 |
| Molecular Formula | C11H12BrFN2O3 |
| Molecular Weight | 319.13 g/mol |
| Exact Mass | 318.00 |
| IUPAC Name | (E)-3-[2-bromo-5-methyl-3-[[(2S)-oxetan-2-yl]methyl]imidazol-4-yl]-2-fluoroprop-2-enoic acid |
| SMILES | Cc1nc(Br)n(C[C@@H]2CCO2)c1/C=C(/F)C(=O)O |
| InChI | InChI=1S/C11H12BrFN2O3/c1-6-9(4-8(13)10(16)17)15(11(12)14-6)5-7-2-3-18-7/h4,7H,2-3,5H2,1H3,(H,16,17)/b8-4+/t7-/m0/s1 |
| InChIKey | CCCWYSPRGYAUMH-PUSOHNNWSA-N |
| XLogP | 2.14 |
| TPSA | 64.35 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 18 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 319.13 |
| LogP ≤ 5 | 2.14 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 4 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'Michael_acceptor_1', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 172694193 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.